Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency

Irritable Bowel Syndrome Clinical Trial

Official title:

A Phase II Study to Identify the Role of Exocrine Pancreatic Insufficiency in Pediatric Patients With Abdominal Pain (RAP) Who Are Undergoing Upper Endoscopy Using Synthetic Human Secretin

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04231279
• Other study ID #: RAP and EPI
• Secondary ID: 1804804
• Status: Terminated
• Phase: Phase 3
• Start date: January 28, 2022
• Est. completion date: June 15, 2023

Study information

• Verified date: April 2024
• Source: Orlando Health, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a 3-year prospective study too identify the role of exocrine pancreatic insufficiency in patients with abdominal pain who are undergoing upper endoscopy. An endoscopic pancreatic function test (ePFT) with secretin will be performed in children undergoing routine investigative EGD. The goal of this study is to identify the role of exocrine pancreatic insufficiency in patients with abdominal pain who are undergoing upper endoscopy, who otherwise would be labelled as recurrent abdominal pain (RAP).

Description:

Recurrent abdominal pain (RAP) is an often encountered complaint in children and adolescents. The evaluation of the child or adolescent with recurrent abdominal pain requires an understanding of the pathogenesis of abdominal pain, the most common causes of abdominal pain, and the typical patterns of presentation. Children and adolescents frequently undergo esophagogastroduodenoscopy (EGD) to evaluate complaint and recurrent abdominal pain is a frequently cited reason for endoscopy. This is a standard procedure where an endoscope is passed through the mouth, esophagus, stomach and into the first part of the small intestine. With the camera at the end of the endoscope, the endoscopist is able to see the gross appearance of the upper digestive tract. Small biopsy samples are collected from the small intestine, stomach and esophagus to evaluate for mucosal injury, irritation, infection or other anomalies that could be contributing to the patient's symptoms. This is helpful for evaluation of histological changes, but does not provide information about its function. Pancreatic stimulation testing with secretagogue (secretin, cholecystokinin) administration, and direct pancreatic fluid collection is considered a gold standard to assess the exocrine pancreatic function. Indirect testing of pancreatic function such as with urine or stool has much lower sensitivity and specificity compared to direct pancreatic fluid collection. This is a prospective study where patients undergoing investigative EGD will have endoscopic pancreatic function test (ePFT) with secretin. There will be two groups: The first group are patients that are undergoing EGD with ePFT for evaluation of suspected or established pancreatic insufficiency with symptoms such as failure to thrive or malabsorption. These patients are the ones that historically have had ePFT testing done to evaluate their pancreatic function. The second group is all patients that are undergoing scheduled diagnostic EGD for other reasons that consent for pancreatic stimulation testing. These patients are usually undergoing EGD for a range of symptoms that frequently include recurrent abdominal pain, bloating, diarrhea, nausea and/or constipation. These patients do not typically have ePFT testing performed and is not usually thought to be part of the standard of care for this group.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 27
• Est. completion date: June 15, 2023
• Est. primary completion date: June 15, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 18 Years

Eligibility

Inclusion Criteria:

• For Group 1- Patients undergoing EGD with ePFT for symptoms of suspected or known pancreatic insufficiency
• For Group 2- Patients undergoing diagnostic EGD who consent to undergo ePFT

Exclusion Criteria:

• If it is an emergency EGD procedure
• If the caregiver refuses to sign the consent form
• Patient has undergone ePFT testing previously with a documented allergy to human secretin
• Patients that require atropine at the time of sedation

Related Conditions & MeSH terms

• Abdominal Pain
• Exocrine Pancreatic Insufficiency
• Irritable Bowel Syndrome

Intervention

Drug:
• synthetic human secretin
Secretin is a gastrointestinal peptide hormone, indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction.

Locations

Country	Name	City	State
United States	Orlando Health - Arnold Palmer Children's Hospital	Orlando	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Orlando Health, Inc.	ChiRhoClin, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of pancreatic insufficiency in Pediatric cases undergoing upper endoscopy for Abdominal Pain	Secretin stimulated exocrine pancreatic enzyme activity will be measured in patients with abdominal pain who are undergoing upper endoscopy to identify those with insufficiency (EPI).	2.5 years
Secondary	Secondary biomarkers for exocrine pancreatic insufficiency in blood and pancreatic fluid will be measured to explore mechanisms involved leading to abdominal pain and become potential tests in future.	This includes immunological and genetic markers.	2.5 years